COMMUNIQUÉS West-GlobeNewswire

Children’s National receives $56.25 million Pediatric Prevention Network award
14/09/2026
Washington, DC, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Children’s National will receive $56.25 million over five years to help lead the Pediatric Prevention Network’s (PPN) work to strengthen pediatric disaster preparedness [...]
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
14/09/2026
NANJING, China, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that updated Phase II data for opamtistomig (LBL-024), its [...]
Etienna Bio Completes FDA INTERACT Meeting for ETB-001
14/09/2026
LEAWOOD, Kan., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Etienna Bio, Inc. today announced that it completed an INTERACT meeting with the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) [...]
Sol y Vida Launches Nationwide Bilingual Telehealth Platform Built for Latino Communities
14/09/2026
Launching ahead of Hispanic Heritage Month, Latino-founded health platform provides English- and Spanish-language access to clinician-led weight management, metabolic health and wellness care LOS ANGELES, Sept. 14, 2026 [...]
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
14/09/2026
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related [...]
Asimov Announces Cell Line Development Partnership with Sidewinder Therapeutics to Advance 4-Chain Bispecific Antibody for Solid Tumors
14/09/2026
As part of a multi-product collaboration, Asimov’s CHO Edge system enabled a high performance cell line for a first-in-class bispecific antibody, achieving clonal titers of over 10 g/L in a platform fed-batch process [...]
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
14/09/2026
Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for [...]
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
14/09/2026
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric adverse events [...]
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
14/09/2026
Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune [...]
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
14/09/2026
Independent DSMB Recommends MediWound’s EscharEx ® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain [...]
Hop Valley Brewing Co. Makes Its Downtown Eugene Comeback with New Pub at 5th Street Public Market
14/09/2026
Hop Valley opens its new pub Sept. 17, giving Ducks fans a new place to rally, celebrate, and raise a pint on game day EUGENE, Ore., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Hop Valley Brewing Co , a trailblazer in the craft [...]
Pharmazz, Inc. Receives U.S. FDA Orphan Drug Designation for Sovateltide for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)
14/09/2026
U.S. FDA (Office of Orphan Products Development) grants Orphan Drug Designation for Sovateltide, a potential first-in-class therapy that could transform the treatment of Neonatal Hypoxic-Ischemic Encephalopathy Five [...]
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
14/09/2026
Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entity HIGHLIGHTS Texas-based company [...]
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
14/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell [...]
Soleo Health Expands Atlanta Footprint With Infusion Centers In Woodstock and Fayetteville, Georgia
14/09/2026
FRISCO, Texas, WOODSTOCK, Ga., and FAYETTEVILLE, Ga., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national, independent provider of complex specialty pharmacy and infusion services , [...]
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
14/09/2026
Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env is found in the [...]
Slate Medicines Appoints Kenneth Koblan, PhD, as Chief Scientific Officer
14/09/2026
RALEIGH, N.C., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Slate Medicines Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and [...]
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
14/09/2026
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 [...]
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
14/09/2026
- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation - [...]

Pages